SEC Form 4 · accession 0001140361-16-057803
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Havey
Officer — EVP, Biodefense Divison
Period of report
Mar 11, 2016
Accepted (ET)
Mar 15, 2016 · 3:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 11, 2016 | M | 7,960 | $14.67 | A | 54,254 | D | |
| Common StockF1,F2,F3 | Mar 11, 2016 | S | 7,960 | $33.84 | D | 46,294 | D | |
| Common StockF2,F4,F5 | Mar 11, 2016 | S | 3,152 | $33.84 | D | 43,142 | D | |
| Common StockF4 | Mar 11, 2016 | F | 1,278 | $34.22 | D | 41,864 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F6 | $14.67 | Mar 11, 2016 | M | 7,960 | A | — | Mar 11, 2020 | Common Stock | 7,960 | 0 | D |
Explanation of responses
- F1Consists of an option granted under the company's stock incentive plan on March 12, 2013.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.56 to $34.14, inclusive.
- F4Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.56 to $34.09, inclusive.
- F6The option vest in three equal installments in March 2014, 2015 and 2016.